Drug Profile
Research programme: cannabinoid receptor agonists - Merck
Alternative Names: ADC X; ADC Y; ADC ZLatest Information Update: 08 Feb 2017
Price :
$50
*
At a glance
- Originator Adolor Corporation
- Class
- Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer pain; Neuropathic pain; Pain
Most Recent Events
- 16 Dec 2011 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
- 16 Dec 2011 Discontinued - Preclinical for Pain in USA (unspecified route)
- 12 Dec 2011 Adolor Corporation has been acquired and merged into Cubist Pharmaceuticals